mTOR抑制剂的漫长历程以及仍在前方的漫长道路。 - Suppr

Suppr

超能文献

The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.

作者信息

Tedesco Silva Helio

出版信息

Transplantation. 2018 Feb;102(2S Suppl 1):S1-S2. doi: 10.1097/TP.0000000000001950.

DOI:10.1097/TP.0000000000001950

PMID:29369969

Abstract

摘要

相似文献

The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.

Transplantation. 2018 Feb;102(2S Suppl 1):S1-S2. doi: 10.1097/TP.0000000000001950.

mTOR Inhibition and Clinical Transplantation: Kidney.

Transplantation. 2018 Feb;102(2S Suppl 1):S17-S18. doi: 10.1097/TP.0000000000001692.

mTOR Inhibition and Clinical Transplantation: Heart.

Transplantation. 2018 Feb;102(2S Suppl 1):S27-S29. doi: 10.1097/TP.0000000000001921.

mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.

Transplantation. 2018 Feb;102(2S Suppl 1):S30-S31. doi: 10.1097/TP.0000000000001700.

mTOR Inhibition and Kidney Diseases.

Transplantation. 2018 Feb;102(2S Suppl 1):S32-S40. doi: 10.1097/TP.0000000000001729.

Transplantation: time to rethink immunosuppression by mTOR inhibitors?

Nat Rev Nephrol. 2009 Nov;5(11):611-2. doi: 10.1038/nrneph.2009.168.

Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature.

Expert Rev Clin Immunol. 2013 Aug;9(8):781-9. doi: 10.1586/1744666X.2013.824243.

mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.

Transplantation. 2018 Feb;102(2S Suppl 1):S41-S43. doi: 10.1097/TP.0000000000001691.

Sirolimus, the first mTOR inhibitor.

Nefrologia. 2006;26 Suppl 2:21-32.

Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients.

Cell Mol Immunol. 2015 Jan;12(1):122-4. doi: 10.1038/cmi.2014.27. Epub 2014 Jun 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.

Transplantation. 2018 Feb;102(2S Suppl 1):S1-S2. doi: 10.1097/TP.0000000000001950.

mTOR Inhibition and Clinical Transplantation: Kidney.

Transplantation. 2018 Feb;102(2S Suppl 1):S17-S18. doi: 10.1097/TP.0000000000001692.

mTOR Inhibition and Clinical Transplantation: Heart.

Transplantation. 2018 Feb;102(2S Suppl 1):S27-S29. doi: 10.1097/TP.0000000000001921.

mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.

Transplantation. 2018 Feb;102(2S Suppl 1):S30-S31. doi: 10.1097/TP.0000000000001700.

mTOR Inhibition and Kidney Diseases.

Transplantation. 2018 Feb;102(2S Suppl 1):S32-S40. doi: 10.1097/TP.0000000000001729.

Transplantation: time to rethink immunosuppression by mTOR inhibitors?

Nat Rev Nephrol. 2009 Nov;5(11):611-2. doi: 10.1038/nrneph.2009.168.

Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature.

Expert Rev Clin Immunol. 2013 Aug;9(8):781-9. doi: 10.1586/1744666X.2013.824243.

mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.

Transplantation. 2018 Feb;102(2S Suppl 1):S41-S43. doi: 10.1097/TP.0000000000001691.

Sirolimus, the first mTOR inhibitor.

Nefrologia. 2006;26 Suppl 2:21-32.

Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients.

Cell Mol Immunol. 2015 Jan;12(1):122-4. doi: 10.1038/cmi.2014.27. Epub 2014 Jun 2.